SLC30A7 phosphorylation by ERK1 promotes esophageal squamous cell carcinoma tumorigenesis via activating MMP2/3/9-β-catenin signaling
Cancer Letters · 2026-09 · 655 · 218623
DOI: 10.1016/j.canlet.2026.218623 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-09. Verfasst von Lu Yang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, China; China-US (Henan) Hormel Cancer Insti…. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Cation Transport Proteins, Esophageal Neoplasms, Mitogen-Activated Protein Kinase 3. Die Arbeit nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, International Science and Technology Cooperation Programme, Zhengzhou University.
Abstract (Originalsprache)
Zinc ions (Zn2+) are crucial for cellular homeostasis, with their intracellular concentrations tightly regulated by multiple zinc transporters located at the plasma and organelle membranes. Zinc dysregulation has been implicated in esophageal squamous cell carcinoma (ESCC), yet the oncogenic roles of zinc transporters remain poorly understood. We herein identify SLC30A7 as a zinc transporter markedly elevated in ESCC and associated with poor prognosis. Genetic deletion of Slc30a7 significantly suppressed 4NQO-induced esophageal tumorigenesis, whereas SLC30A7 knockdown inhibited ESCC cell proliferation, migration, and tumor progression. Mechanistically, ERK1 specifically binds SLC30A7 and phosphorylates SLC30A7 at T297 site, driving the redistribution of zinc (Zn2+) from the cytosol into the Golgi lumen. SLC30A7 cooperates with the zinc metallochaperone ZNG1 to mobilize Golgi-resident zinc toward matrix metalloproteinases MMP2/3/9 activation, leading to E-cadherin degradation, β-catenin nuclear translocation, and MYC transcription. In ESCC PDX models, a tumor-targeted biomimetic ERK inhibitor nanoplatform (Q3ME@PBA-NPs) significantly restrained tumor growth and disrupted the ERK1-SLC30A7-MMP2/3/9-β-catenin-c-Myc axis. These findings reveal a previously unrecognized zinc-dependent oncogenic pathway in ESCC and highlight SLC30A7 as a valuable therapeutic target in cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, China; China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450003, China; Tianjian Laboratory of Advanced Biomed…
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450003, China.
- Henan Key Laboratory of Chronic Disease Management, Fuwai Central China Cardiovascular 10 Hospital, Zhengzhou, 450000, China. Electronic address: weijiang@zzu.edu.cn.
Förderung
- National Natural Science Foundation of China
- International Science and Technology Cooperation Programme
- Zhengzhou University
Zitieren
APA
Yang, L., Yao, N., Zhou, L., Zhou, R., Wang, J., Yang, R., Fan, Y., Nie, W., Liu, K., Jiang, W., Kim, D. J., Dong, Z., & Li, X. (2026). SLC30A7 phosphorylation by ERK1 promotes esophageal squamous cell carcinoma tumorigenesis via activating MMP2/3/9-β-catenin signaling. Cancer Letters, 655, 218623. https://doi.org/10.1016/j.canlet.2026.218623
Vancouver
Yang L, Yao N, Zhou L, Zhou R, Wang J, Yang R, et al. SLC30A7 phosphorylation by ERK1 promotes esophageal squamous cell carcinoma tumorigenesis via activating MMP2/3/9-β-catenin signaling. Cancer Letters. 2026;655:218623. doi:10.1016/j.canlet.2026.218623
BibTeX
@article{Yang2026,
author = {Yang, Lu and Yao, Ning and Zhou, Liting and Zhou, Ran and Wang, Jiutao and Yang, Ran and Fan, Yanle and Nie, Wenna and Liu, Kangdong and Jiang, Wei and Kim, Dong Joon and Dong, Zigang and Li, Xiang},
title = {SLC30A7 phosphorylation by ERK1 promotes esophageal squamous cell carcinoma tumorigenesis via activating MMP2/3/9-β-catenin signaling},
journal = {Cancer Letters},
year = {2026},
volume = {655},
pages = {218623},
doi = {10.1016/j.canlet.2026.218623}
}
EUVIMED